Monod Bio
Daniel-Adriano S. has a diverse work experience encompassing various roles and companies. Currently, they are serving as the CEO and President of Monod Bio from November 2021. Prior to this, they worked at Neoleukin Therapeutics as VP Head Of Research and Cofounder from April 2019 to March 2021. Before that, they held positions at the University of Washington, where they served as an Acting Instructor and Translational Scientist from May 2018 to April 2019, and as a Senior Research Fellow from January 2013 to May 2018. Daniel-Adriano'searlier experience includes working as a Research Associate at HKUST from July 2010 to January 2013.
Daniel-Adriano S. completed their formal education at the Universidad Nacional Autónoma de México. Daniel-Adriano first obtained a Bachelor of Basic Biomedical Research degree in 2007. Following this, they pursued a Master of Science in Biochemistry from 2007 to 2009. Subsequently, they continued their studies at the same university to earn a Doctor of Philosophy (Ph.D.) degree in Biochemistry, which they completed in 2012.
Monod Bio
Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid,sensitive, and inexpensive analytical assays.Monod Bio was founded in 2021 and is headquartered in Seattle, Washington.